Akèy › Limfom Difize Gwo Selil B › New York › New York City
Etid klinik pou Limfom Difize Gwo Selil B nan New York City, NY
21 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Ap rekriteFaz 2
- Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai ( Site 0164), New York
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108), New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Columbia University, New York
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Ap rekriteFaz 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Ap rekriteFaz 1 bonè
- Memorial Sloan Kettering Cancer Center, New York
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Ap rekriteFaz 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Ap rekrite
- Columbia University, New York
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Ap rekriteFaz 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Ap rekrite
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
Etid Limfom Difize Gwo Selil B nan lòt vil
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Houston, TX17 etid
- Los Angeles, CA17 etid
- Milwaukee, WI16 etid
- Boston, MA16 etid
- Nashville, TN15 etid
- Philadelphia, PA15 etid
- Portland, OR15 etid
- Durham, NC14 etid
- Dallas, TX13 etid
- Washington, DC12 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.